Home > Insider Trading > Filing (0001127602-20-018531)

Filing Details

Accession Number:: 0001127602-20-018531
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-06-02 19:40:45
Reporting Period:: 2020-05-29

Accepted Time:: 2020-06-02 19:40:45
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1682852	Moderna Inc.	MRNA	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1443340	Stephane Bancel	C/O Moderna, Inc. 200 Technology Square Cambridge MA 02139	Chief Executive Officer	Yes	Yes	No	No

Transaction Summary

Sold:	30,558 shares	Avg. Price: $60.99	Total Value: $1,863,704.14
Number of Shares After Transactions:	9,193,839 shares

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2020-05-29	2,763	$57.49	582,691	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2020-05-29	7,820	$58.03	574,871	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2020-05-29	463	$61.01	574,408	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2020-06-01	4,878	$62.67	6,729,980	No	4	S	Direct
Common Stock	Disposition	2020-06-01	9,756	$62.67	7,875,124	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2020-06-01	4,878	$62.67	9,193,839	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Direct
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Footnotes

This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $56.72 to $57.72. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $57.75 to $58.60. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.12 to $61.38. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/18/2018.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/18/2018, and amended on 9/16/2019.
These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.